Zhimin Shao

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

Gϋnter von Minckwitz, Chiun‐Sheng Huang, Max S. Mano et al. · New England Journal of Medicine · 2018 · 2.6K citations · Full text

Medicine, Oncology, Pharmacology +17

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2021 · 729 citations · Full text

Medicine, Oncology, Pharmacology +17

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

Nadia Harbeck, Priya Rastogi, Miguel Martín et al. · Annals of Oncology · 2021 · 378 citations · Full text

Medicine, Oncology, Pharmacology +16

A multi-centre randomised trial comparing ultrasound vs mammography for screening breast cancer in high-risk Chinese women

Songjie Shen, Yidong Zhou, Yingyang Xu et al. · British Journal of Cancer · 2015 · 198 citations · Full text

Medicine, Oncology, Preventive Medicine +15

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer

Charles E. Geyer, M. Untch, Chiun‐Sheng Huang et al. · New England Journal of Medicine · 2025 · 115 citations · Full text

Medicine, Oncology, Pharmacology +14